Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96601 | 0.94 | KCNA3 (0.67) | KCNA3TAAR1ALDH1A1RECQLHDAC3 | |
| SCHEMBL7500084 | 0.92 | KCNA3 (0.64) | KCNA3TAAR1ALDH1A1RECQLHDAC3 | |
| SCHEMBL11578031 | 0.92 | KCNA3 (0.64) | KCNA3TAAR1ALDH1A1RECQLHDAC3 | |
| SCHEMBL11617118 | 0.92 | KCNA3 (0.64) | KCNA3TAAR1ALDH1A1RECQLHDAC3 | |
| SCHEMBL96054 | 0.92 | KCNA3 (0.64) | KCNA3TAAR1ALDH1A1RECQLHDAC3 | |
| SCHEMBL43676 | 0.89 | KCNA3 (0.58) | KCNA3TAAR1ALDH1A1RECQLHDAC3 | |
| SCHEMBL5255125 | 0.88 | LSS (0.54) | KCNA3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7363050 | 0.82 | KCNA3 (0.50) | KCNA3TAAR1ALDH1A1RECQLHDAC3 | |
| SCHEMBL2068603 | 0.80 | KCNA3 (0.65) | KCNA3TAAR1ALDH1A1RECQLHDAC3 | |
| SCHEMBL5540265 | 0.79 | KDM4E (0.46) | ALDH1A1DRD2DRD4DRD3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | claimed |
| US-4117145-A | DIURETIC, HYPOTENSIVE, ANTITHROMBOTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-26 | — | — | US | claimed |
| US-4117143-A | USED AS ANTITHROMBOTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-26 | — | — | US | claimed |
| CN-116121316-A | Process for the manufacture of L-glufosinate | 巴斯夫欧洲公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-116121315-A | Process for the manufacture of L-glufosinate | 巴斯夫欧洲公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-109072261-B | Process for producing L-glufosinate | 巴斯夫欧洲公司 | 2023-03-17 | — | — | CN | disclosed |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-3998805-A | MONOAZO DYES; POLYESTERS; YELLOW, RED, OR ORANGE SHADES | CIBA-GEIGY CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
| US-3989685-A | FROM PENICILLIN-1-OXIDE | SHINOGI & CO., LTD. (JA) | 1976-11-02 | — | — | US | disclosed |
| US-3984397-A | CYCLIZATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-10-05 | — | — | US | disclosed |
| US-3984403-A | PAINLESS INTRAMUSCULAR INJECTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-10-05 | — | — | US | disclosed |
| US-3954732-A | BACTERICIDAL PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-05-04 | — | — | US | disclosed |
| US-3933806-A | Cephalosporin michael adducts | ELI LILLY AND COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | KCNA3 3623/4885TAAR1 4623/4885ALDH1A1 4023/4885 |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | KCNA3 3623/4885TAAR1 4623/4885ALDH1A1 4023/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | KCNA3 3623/4885TAAR1 4623/4885ALDH1A1 4023/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | KCNA3 3623/4885TAAR1 4623/4885ALDH1A1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.